About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNCT04728880

Remdesivir in Adults With Covid-19: Mansoura University Hospital Experience

COVID-19 is a respiratory disease caused by a new coronavirus (SARS-CoV-2) and causes significant morbidity and mortality. This study is a retrospective trial to assess the efficacy of Remdesivir in a...

Lead sponsor: Mansoura University•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Mansoura University

COVID-19 is a novel respiratory disease caused by coronavirus (SARS-CoV-2) and results in significant morbidity and mortality. To date there is no approved medication for the treatment of patients with COVID-19. Remdesivir is a broad-spectrum antiviral nucleotide analogue that inhibits RNA-dependent RNA polymerase activity among a diverse group of RNA viruses. Non-clinical and clinical data suggest that Remdesivir may be useful for the treatment of COVID-19. WHO has identified Remdesivir as a candidate drug of interest to be studied in clinical trials. This retrospective study is designed to analyze the data collected during the routine care of patients who have benefited from this therapy.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Adult ≥ 18 years old.
•2. SARS-CoV-2 infection confirmed.
•3. Patients having classical radiological lesions of COVID-19 on X-ray chest or HRCT chest.
•4. Hospitalized patients who received at least one administration of Remdesivir therapy (Dose: 200mg day one then 100mg daily for up to 10 days).

Exclusion Criteria

•1. Presences of chronic renal failure \> 4 stage, GFR \< 30ml/min.
•2. ALT/AST \> 5 times than normal values.
•3. Pregnant women.

Related studies

Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients

NCT05976581 · Pneumonia, Pneumonia, Viral, and more

COMPLETEDPhase 1

A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC (Phase 1)

NCT04830800 · COVID-19 Disease, SARS Pneumonia, and more

TERMINATEDPhase 3

Cromolyn Sodium for Treatment of COVID-19 Pneumonia

NCT05077917 · COVID-19 Pneumonia, COVID-19 Respiratory Infection, and more

COMPLETEDPhase 2

Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS

NCT04429555 · Pneumonia, Viral

Tobacco Use and the Risk of COVID-19 and Adverse Outcomes

NCT05321433 · COVID-19, Respiratory Tract Infections, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 28, 2021Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment300

Start dateJan 2021

Last updatedJan 28, 2021

Condition

Pneumonia, Viral

Locations shown

Mansoura University Hospital

Al Mansurah, Dakahliya

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 28, 2021Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions